353 related articles for article (PubMed ID: 20719940)
1. Histone deacetylase: a potential therapeutic target for fibrotic disorders.
Pang M; Zhuang S
J Pharmacol Exp Ther; 2010 Nov; 335(2):266-72. PubMed ID: 20719940
[TBL] [Abstract][Full Text] [Related]
2. The roles of histone deacetylases in kidney development and disease.
Liu H
Clin Exp Nephrol; 2021 Mar; 25(3):215-223. PubMed ID: 33398599
[TBL] [Abstract][Full Text] [Related]
3. Histone deacetylases in cardiac fibrosis: current perspectives for therapy.
Tao H; Shi KH; Yang JJ; Huang C; Zhan HY; Li J
Cell Signal; 2014 Mar; 26(3):521-7. PubMed ID: 24321371
[TBL] [Abstract][Full Text] [Related]
4. Histone deacetylases in cardiovascular and metabolic diseases.
Bagchi RA; Weeks KL
J Mol Cell Cardiol; 2019 May; 130():151-159. PubMed ID: 30978343
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic effects of histone deacetylase inhibitors on heart disease.
Chun P
Arch Pharm Res; 2020 Dec; 43(12):1276-1296. PubMed ID: 33245518
[TBL] [Abstract][Full Text] [Related]
6. Targeting Histone Deacetylases in Idiopathic Pulmonary Fibrosis: A Future Therapeutic Option.
Korfei M; Mahavadi P; Guenther A
Cells; 2022 May; 11(10):. PubMed ID: 35626663
[TBL] [Abstract][Full Text] [Related]
7. Roles and targets of class I and IIa histone deacetylases in cardiac hypertrophy.
Kee HJ; Kook H
J Biomed Biotechnol; 2011; 2011():928326. PubMed ID: 21151616
[TBL] [Abstract][Full Text] [Related]
8. The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis.
Conforti F; Davies ER; Calderwood CJ; Thatcher TH; Jones MG; Smart DE; Mahajan S; Alzetani A; Havelock T; Maher TM; Molyneaux PL; Thorley AJ; Tetley TD; Warner JA; Packham G; Ganesan A; Skipp PJ; Marshall BJ; Richeldi L; Sime PJ; O'Reilly KMA; Davies DE
Oncotarget; 2017 Jul; 8(30):48737-48754. PubMed ID: 28467787
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic effects of histone deacetylase inhibitors on kidney disease.
Chun P
Arch Pharm Res; 2018 Feb; 41(2):162-183. PubMed ID: 29230688
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic modifications by histone deacetylases: Biological implications and therapeutic potential in liver fibrosis.
Chen PJ; Huang C; Meng XM; Li J
Biochimie; 2015 Sep; 116():61-9. PubMed ID: 26116886
[TBL] [Abstract][Full Text] [Related]
11. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy.
Kong Y; Tannous P; Lu G; Berenji K; Rothermel BA; Olson EN; Hill JA
Circulation; 2006 Jun; 113(22):2579-88. PubMed ID: 16735673
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats.
Kang SH; Seok YM; Song MJ; Lee HA; Kurz T; Kim I
Mol Pharmacol; 2015 May; 87(5):782-91. PubMed ID: 25667225
[TBL] [Abstract][Full Text] [Related]
13. HDAC inhibitors in kidney development and disease.
Brilli LL; Swanhart LM; de Caestecker MP; Hukriede NA
Pediatr Nephrol; 2013 Oct; 28(10):1909-21. PubMed ID: 23052657
[TBL] [Abstract][Full Text] [Related]
14. Anti-fibrotic effects of valproic acid: role of HDAC inhibition and associated mechanisms.
Khan S; Ahirwar K; Jena G
Epigenomics; 2016 Aug; 8(8):1087-101. PubMed ID: 27411759
[TBL] [Abstract][Full Text] [Related]
15. HDACs and HDAC Inhibitors in Cancer Development and Therapy.
Li Y; Seto E
Cold Spring Harb Perspect Med; 2016 Oct; 6(10):. PubMed ID: 27599530
[TBL] [Abstract][Full Text] [Related]
16. Emodin and emodin-rich rhubarb inhibits histone deacetylase (HDAC) activity and cardiac myocyte hypertrophy.
Evans LW; Bender A; Burnett L; Godoy L; Shen Y; Staten D; Zhou T; Angermann JE; Ferguson BS
J Nutr Biochem; 2020 May; 79():108339. PubMed ID: 32007664
[TBL] [Abstract][Full Text] [Related]
17. Targeting histone deacetylases for heart failure.
Bush EW; McKinsey TA
Expert Opin Ther Targets; 2009 Jul; 13(7):767-84. PubMed ID: 19466913
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylases as targets for treatment of multiple diseases.
Tang J; Yan H; Zhuang S
Clin Sci (Lond); 2013 Jun; 124(11):651-62. PubMed ID: 23414309
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylases in kidney development: implications for disease and therapy.
Chen S; El-Dahr SS
Pediatr Nephrol; 2013 May; 28(5):689-98. PubMed ID: 22722820
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the antifibrotic effects of the pan-histone deacetylase-inhibitor panobinostat versus the IPF-drug pirfenidone in fibroblasts from patients with idiopathic pulmonary fibrosis.
Korfei M; Stelmaszek D; MacKenzie B; Skwarna S; Chillappagari S; Bach AC; Ruppert C; Saito S; Mahavadi P; Klepetko W; Fink L; Seeger W; Lasky JA; Pullamsetti SS; Krämer OH; Guenther A
PLoS One; 2018; 13(11):e0207915. PubMed ID: 30481203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
